Leukemia Clinical Trials

50 trials recruiting in Canada.

Cancer

Recruiting Drug Device Behavioral Older adults Healthy volunteers

35 trials · showing 30

Testing Elritercept against a placebo for myelodysplastic syndromes

Explore this study →

There are 2 groups in this study. Group A receives Elritercept. Group B, the placebo group, receives Placebo.

Sites in Toronto, Edmonton and 3 more cities

Phase 3
2 groups
Sites in Edmonton, Vancouver and 3 more cities
Recruiting

Official title: A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

Myelodysplastic Syndromes · Takeda

Comparing Nemtabrutinib with Rituximab for leukemia, lymphocytic, chronic, b-cell

Explore this study →

There are 2 groups in this study. Group A receives Nemtabrutinib and Venetoclax. Group B, the comparison group, receives Venetoclax and Rituximab.

Sites in Greenfield Park, Kingston and 2 more cities

Phase 3
2 groups
Sites in Moncton, Kingston and 2 more cities
Recruiting

Official title: A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

Leukemia, Lymphocytic, Chronic, B-Cell · Merck Sharp & Dohme LLC

Comparing Biospecimen Collection with Bone Marrow Aspiration for chronic lymphocytic leukemia

Explore this study →

There are 2 groups in this study. Group A, the comparison group, receives one or more of: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Obinutuzumab, Questionnaire Administration and Venetoclax. Group B receives one or more of: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Obinutuzumab, Questionnaire Administration and Venetoclax.

Sites in Halifax, Montreal and 6 more cities

Phase 3
2 groups
Sites in Vancouver, Winnipeg and 6 more cities
Recruiting

Official title: Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Chronic Lymphocytic Leukemia · National Cancer Institute (NCI)

Get matched to the best-fit trials

Answer a few questions and we'll find the closest matches for leukemia.

Testing EASE-psy for acute leukemia

Explore this study →

There are 2 groups in this study. Group A receives Usual Care. Group B receives EASE-psy.

Sites in Toronto, Hamilton and 3 more cities

2 groups
Sites in Saint John, Hamilton and 3 more cities
Recruiting

Official title: Emotion and Symptom-Focused Engagement Trial for Individuals With Acute Leukemia

Acute Leukemia · Canadian Cancer Trials Group

Testing CLIC-2201 for b-cell leukemia

Explore this study →

Everyone in this study is in one group and receives CLIC-2201.

Sites in Calgary, Toronto and 2 more cities

Phase 1
1 group
Sites in Calgary, Vancouver and 2 more cities
Recruiting

Official title: CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

B-Cell Leukemia · British Columbia Cancer Agency

Comparing 11 approaches for chronic myelogenous leukemia

Explore this study →

There are 11 groups in this study. Groups A, C and J receive Asciminib single agent. Group B receives Bosutinib. Groups D and F receive Imatinib. …and 3 more groups.

One site, in Montreal

Phase 4
11 groups
One site, in Montreal
Recruiting

Official title: Asciminib Roll-over Study

Chronic Myelogenous Leukemia · Novartis Pharmaceuticals

Comparing 3 approaches for chronic lymphocytic leukemia

Explore this study →

There are 3 groups in this study. Groups A and C receive Pirtobrutinib. Group B, the comparison group, receives Ibrutinib.

Sites in Montreal, Québec and 1 more city

Phase 3
3 groups
Sites in Montreal, Québec and 1 more city
Recruiting

Official title: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Chronic Lymphocytic Leukemia · Loxo Oncology, Inc.

Testing Ziftomenib against a placebo for acute myeloid leukemia (AML)

Explore this study →

There are 5 groups in this study. Group A receives one or more of: Ziftomenib, Venetoclax and Azacitidine (AZA). Group B, the placebo group, receives one or more of: Placebo, Venetoclax and Azacitidine (AZA). Group C receives one or more of: Ziftomenib, Daunorubicin and Cytarabine (Ara-C). …and 2 more groups.

One site, in Montreal

Phase 3
5 groups
One site, in Montreal
Recruiting

Official title: Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Acute Myeloid Leukemia (AML) · Kura Oncology, Inc.

Testing Tranexamic acid against a placebo for myelodysplastic syndromes

Explore this study →

There are 2 groups in this study. Group A receives Tranexamic acid. Group B, the placebo group, receives Placebo.

One site, in Winnipeg

Phase 2
2 groups
One site, in Winnipeg
Recruiting

Official title: Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia

Myelodysplastic Syndromes · University of Manitoba

Comparing 14 approaches for leukemia, myeloid, acute

Explore this study →

There are 14 groups in this study. Groups A, C, D, G, H and I receive Enzomenib. Groups B, J and K receive one or more of: Enzomenib and azoles. Group E receives one or more of: Enzomenib, Venetoclax and Azacitidine (AZA). …and 3 more groups.

Sites in Calgary and Edmonton

Phase 1
14 groups
Sites in Calgary and Edmonton
Recruiting

Official title: A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Leukemia, Myeloid, Acute · Sumitomo Pharma America, Inc.

Testing Ibrutinib for chronic lymphocytic leukemia

Explore this study →

Everyone in this study is in one group and receives Ibrutinib.

One site, in Montreal

Phase 3
1 group
One site, in Montreal
Recruiting

Official title: A Long-term Extension Study of PCI-32765 (Ibrutinib)

Chronic Lymphocytic Leukemia · Janssen Research & Development, LLC

Comparing 4 approaches for chronic lymphocytic leukemia

Explore this study →

There are 4 groups in this study. Group A, the comparison group, receives Pirtobrutinib. Groups B, C and D receive Pirtobrutinib.

Sites in Barrie and Saskatoon

Phase 2
4 groups
Sites in Barrie and Saskatoon
Recruiting

Official title: A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia · Loxo Oncology, Inc.

Testing AZD4512 monotherapy for b-cell acute lymphoblastic leukemia (b-ALL)

Explore this study →

There are 2 groups in this study. Groups A and B receive AZD4512 monotherapy.

Sites in Toronto and Vancouver

Phase 1
2 groups
Sites in Vancouver and Toronto
Recruiting

Official title: Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

B-cell Acute Lymphoblastic Leukemia (B-ALL) · AstraZeneca

Testing RBC transfusion strategy for acute leukemia

Explore this study →

There are 2 groups in this study. Group A receives RBC transfusion strategy. Group B receives no study treatment and is followed for comparison.

One site, in Hamilton

2 groups
One site, in Hamilton
Recruiting

Official title: Biomarkers in Patients With Anemia-Induced Thrombocytopenic Bleeding

Acute Leukemia · Donald Arnold

Comparing Nemtabrutinib with Ibrutinib for chronic lymphocytic leukemia

Explore this study →

There are 2 groups in this study. Group A receives Nemtabrutinib. Group B, the comparison group, receives Ibrutinib and Acalabrutinib.

Sites in Brampton, Kelowna and 4 more cities

Phase 3
2 groups
Sites in Kelowna, Victoria and 4 more cities
Recruiting

Official title: A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Chronic Lymphocytic Leukemia · Merck Sharp & Dohme LLC

Comparing 6 approaches for myelodysplastic syndromes

Explore this study →

There are 6 groups in this study. Groups A and B receive one or more of: Azacitidine, ASTX030 (cedazuridine + azacitidine) and Cedazuridine. Groups C and D receive one or more of: ASTX030 (cedazuridine + azacitidine) and Azacitidine. Group E receives one or more of: ASTX030 (cedazuridine + azacitidine), Azacitidine and Venetoclax. …and 1 more groups.

Sites in St. John's and Toronto

Phase 2
6 groups
Sites in St. John's and Toronto
Recruiting

Official title: A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Myelodysplastic Syndromes · Taiho Oncology, Inc.

Testing RBC transfusion for myelodysplastic syndrome

Explore this study →

There are 2 groups in this study. Group A receives RBC transfusion. Group B, the comparison group, receives RBC transfusion.

One site, in Hamilton

2 groups
One site, in Hamilton
Recruiting

Official title: Revisiting the Universal Donor: Does Exposure to O Blood Products Affect Patient Outcomes?

Myelodysplastic Syndrome · McMaster University

Testing Bleximenib for acute leukemia

Explore this study →

Everyone in this study is in one group and receives Bleximenib.

Sites in Montreal, Toronto and 1 more city

Phase 1
1 group
Sites in Vancouver, Toronto and 1 more city
Recruiting

Official title: A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

Acute Leukemia · Janssen Research & Development, LLC

Testing Luspatercept for myelodysplastic syndromes (MDS)

Explore this study →

Everyone in this study is in one group and receives Luspatercept.

3 sites in Toronto

Phase 3
1 group
3 sites in Toronto
Recruiting

Official title: A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Myelodysplastic Syndromes (MDS) · Celgene

Testing CLIC-1901 for acute lymphoblastic leukemia

Explore this study →

Everyone in this study is in one group and receives CLIC-1901.

Sites in Ottawa, Vancouver and 1 more city

Phase 1
1 group
Sites in Vancouver, Winnipeg and 1 more city
Recruiting

Official title: CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies

Acute Lymphoblastic Leukemia · Ottawa Hospital Research Institute

Testing Bleximenib with Venetoclax against a placebo for leukemia, myeloid, acute

Explore this study →

There are 2 groups in this study. Group A receives Bleximenib, Venetoclax (VEN) and Azacitidine (AZA). Group B, the placebo group, receives Placebo, Venetoclax (VEN) and Azacitidine (AZA).

Sites in Calgary, Halifax and 6 more cities

Phase 3
2 groups
Sites in Calgary, Vancouver and 6 more cities
Recruiting

Official title: A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute · Janssen Research & Development, LLC

Comparing Pirtobrutinib with Idelalisib for chronic lymphocytic leukemia

Explore this study →

There are 2 groups in this study. Group A receives Pirtobrutinib. Group B receives Idelalisib.

One site, in Toronto

Phase 4
2 groups
One site, in Toronto
Recruiting

Official title: A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia · Eli Lilly and Company

Testing revumenib with cobicistat for acute myeloid leukemia

Explore this study →

Everyone in this study receives revumenib, together with one or more of: cobicistat.

2 sites in Toronto

Phase 1
1 group
2 sites in Toronto
Recruiting

Official title: A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Acute Myeloid Leukemia · Syndax Pharmaceuticals

Comparing 7 approaches for acute lymphoblastic leukaemia

Explore this study →

There are 7 groups in this study. Groups A, B, C, D, E and F receive AZD3632. Group G receives AZD3632 and Posaconazole.

Sites in Montreal and Toronto

Phase 1
7 groups
Sites in Toronto and Montreal
Recruiting

Official title: Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

Acute Lymphoblastic Leukaemia · AstraZeneca

Comparing 3 approaches for acute myeloid leukemia

Explore this study →

There are 3 groups in this study. Group A receives BMS-986497. Group B receives BMS-986497, together with one or more of: Azacitidine. Group C receives BMS-986497, together with one or more of: Azacitidine and Venetoclax.

Sites in Montreal and Toronto

Phase 1
3 groups
Sites in Toronto and Montreal
Recruiting

Official title: Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia · Bristol-Myers Squibb

Comparing 3 approaches for chronic myeloid leukemia

Explore this study →

There are 3 groups in this study. Groups A, B and C receive ELVN-001.

One site, in Toronto

Phase 1
3 groups
One site, in Toronto
Recruiting

Official title: A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

Chronic Myeloid Leukemia · Enliven Therapeutics

Comparing 4 approaches for b-cell acute lymphoblastic leukemia (b-ALL)

Explore this study →

There are 4 groups in this study. Groups A, B, C and D receive Surovatamig.

Sites in Montreal and Toronto

Phase 1
4 groups
Sites in Toronto and Montreal
Recruiting

Official title: AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

B-cell Acute Lymphoblastic Leukemia (B-ALL) · AstraZeneca

Comparing Sonrotoclax with Acalabrutinib for chronic lymphocytic leukemia

Explore this study →

There are 2 groups in this study. Group A receives Sonrotoclax and Zanubrutinib. Group B, the comparison group, receives Venetoclax and Acalabrutinib.

Sites in Montreal, Hamilton and 3 more cities

Phase 3
2 groups
Sites in Victoria, Hamilton and 3 more cities
Recruiting

Official title: A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia · BeOne Medicines

Testing Revumenib with Intensive Chemotherapy Regimen against a placebo for acute myeloid leukemias

Explore this study →

There are 2 groups in this study. Group A receives Revumenib, together with one or more of: Intensive Chemotherapy Regimen. Group B, the placebo group, receives Placebo, together with one or more of: Intensive Chemotherapy Regimen.

Sites in Montreal and Toronto

Phase 3
2 groups
Sites in Montreal and Toronto
Recruiting

Official title: Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

Acute Myeloid Leukemias · Syndax Pharmaceuticals

Comparing 4 approaches for chronic lymphocytic leukemia

Explore this study →

There are 4 groups in this study. Groups A and C receive Sonrotoclax and Obinutuzumab. Group B receives Sonrotoclax and Rituximab. Group D, the comparison group, receives Venetoclax and Rituximab.

Sites in Calgary, Edmonton and 7 more cities

Phase 3
4 groups
Sites in Calgary, Edmonton and 7 more cities
Recruiting

Official title: A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

Chronic Lymphocytic Leukemia · BeOne Medicines

Looking for the closest fit?

Get matched →

Ask someone to look with you

Whether or not the results above are what you were looking for, someone at Concord can search with you.

Get notified when a matching trial opens

We'll watch for Leukemia trials near you.

← Back to all conditions

Concord provides information support only. Trial listings come from public registries; eligibility is always determined by the trial site and your care team.